Alkermes plans to move ALKS 8700, a novel monomethyl fumarate (MMF) molecule and a competitor for Biogen Idec's successful oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), into pivotal studies following a large, placebo-controlled Phase I clinical trial.
Alkermes plans to move ALKS 8700, a novel monomethyl fumarate (MMF) molecule and a competitor for Biogen Idec's successful oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), into pivotal studies following a large, placebo-controlled Phase I clinical trial.
ALKS 8700 showed less variability and improved gastrointestinal tolerability compared with Tecfidera, according to top-line results from the trial, so...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
